Thus, at least within the TDLN, where initial priming of the anti-tumor effector response is likely occurring, in vivo GITR ligation does not appear to systemically alter the capacity of Tregs or CD8+ Teffs to suppress or be suppressed, respectively. Here, TNFRSF18 is linked to neoplasm.